Voyager Therapeutics, Inc.
VYGR
$3.47
-$0.06-1.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -65.00M | 25.88M | 9.02M | -3.04M | 132.33M |
| Total Depreciation and Amortization | 4.73M | 5.06M | 4.87M | 4.56M | 4.44M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.10M | 9.13M | 8.66M | 6.82M | 7.71M |
| Change in Net Operating Assets | 34.86M | -64.61M | -40.17M | 4.78M | -66.56M |
| Cash from Operations | -15.31M | -24.54M | -17.62M | 13.12M | 77.92M |
| Capital Expenditure | -3.52M | -4.12M | -4.65M | -4.89M | -3.26M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -91.34M | -36.70M | -258.83M | -247.31M | -138.39M |
| Cash from Investing | -94.86M | -40.82M | -263.48M | -252.20M | -141.64M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 114.02M | 113.90M | 114.22M | 115.20M | 33.65M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 114.02M | 113.90M | 114.22M | 115.20M | 33.65M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.85M | 48.54M | -166.89M | -123.88M | -30.08M |